Novo Nordisk Stock Falls on Earnings Miss Amid Eli Lilly Rivalry
Novo Nordisk stock plummeted Tuesday after the drugmaker reported lighter-than-expected June-quarter sales for its new obesity-fighting pill, intensifying a high-stakes market battle with rival Eli Lilly. According to Investor’s Business Daily, the company’s Wegovy pill generated about $496 million during the second quarter, missing analyst forecasts of $509 million and sending shares down more than … Read more